The Centers for Medicare and Medicaid Services has agreed to provide national Medicare coverage of mitral valve transcatheter edge-to-edge repair (TEER) under a new coverage with evidence development (CED) policy issued on 19 January.
Abbott ’s MitraClip, which clips together the ends of the mitral valve leaflets, is the only TEER device currently approved by the US Food and Drug Administration. CMS’ decision relies heavily on evidence from clinical trials of MitraClip, sponsored by Abbott, including